A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement.

Study Overview

• Status: Completed
• Conditions: Neutropenia
• Intervention / Treatment: Drug: tbo-filgrastim

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 2

Contacts and Locations

Study Locations

• Bulgaria
  • Sofia, Bulgaria, 15257
    • Teva Investigational Site 59104
  • Varna, Bulgaria, 9010
    • Teva Investigational Site 59105
• Croatia
  • Rijeka, Croatia, 51000
    • Teva Investigational Site 60015
  • Zagreb, Croatia, 10000
    • Teva Investigational Site 60014
  • Zagreb, Croatia, 10000
    • Teva Investigational Site 60016
• Hungary
  • Budapest, Hungary, 1089
    • Teva Investigational Site 51186
  • Budapest, Hungary, 1094
    • Teva Investigational Site 51185
  • Szeged, Hungary, 6725
    • Teva Investigational Site 51184
• Poland
  • Gdansk, Poland, 80-952
    • Teva Investigational Site 53249
  • Lublin, Poland, 20-093
    • Teva Investigational Site 53248
  • Warszawa, Poland, 01-211
    • Teva Investigational Site 53245
  • Warszawa, Poland, 04-730
    • Teva Investigational Site 53246
  • Wroclaw, Poland, 50-556
    • Teva Investigational Site 53247
• Romania
  • Bucharest, Romania, 022328
    • Teva Investigational Site 52063
  • Cluj-Napoca, Cluj, Romania, 400015
    • Teva Investigational Site 52064
  • Timisoara, Romania, 300383
    • Teva Investigational Site 52065
• Russian Federation
  • Chelyabinsk, Russian Federation, 454076
    • Teva Investigational Site 50282
  • Krasnodar, Russian Federation, 350007
    • Teva Investigational Site 50281
  • Moscow, Russian Federation, 117198
    • Teva Investigational Site 50284
  • St. Petersburg, Russian Federation, 197110
    • Teva Investigational Site 50280
  • Volgograd, Russian Federation, 400138
    • Teva Investigational Site 50283
• Ukraine
  • Kharkiv, Ukraine, 61070
    • Teva Investigational Site 58147
  • Kyiv, Ukraine, 03022
    • Teva Investigational Site 58145
  • Lviv, Ukraine, 79035
    • Teva Investigational Site 58148
  • Vinnytsya, Ukraine, 21029
    • Teva Investigational Site 58146
  • Vinnytsya, Ukraine, 21029
    • Teva Investigational Site 58149
• United States
  • California
    • Long Beach, California, United States, 90806
      • Teva Investigational Site 12958
    • Los Angeles, California, United States, 90024
      • Teva Investigational Site 12951
  • Mississippi
    • Jackson, Mississippi, United States, 39216
      • Teva Investigational Site 12954
  • Nevada
    • Las Vegas, Nevada, United States, 89109
      • Teva Investigational Site 12953
  • New York
    • Valhalla, New York, United States, 10595
      • Teva Investigational Site 12959
  • Ohio
    • Columbus, Ohio, United States, 43205
      • Teva Investigational Site 12960
  • Texas
    • Houston, Texas, United States, 77030
      • Teva Investigational Site 12957

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 16 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion:

1. Male or female infants, children and adolescents aged 1 month to <16 years.
2. Patients with solid tumors without bone marrow involvement, who are scheduled to receive myelosuppressive CTX.
3. Body weight ≥5 kg.

4. Patients must have an initial diagnosis and histologic proof of their malignancy. All enrolled subjects should have signed consent for a CTX regimen that is known to be myelotoxic, with counts expected to drop below the absolute neutrophil count (ANC) of 0.5 × 109/L for at least 3 days. These regimens would include at least one of the following:

   • Etoposide
   • doxorubicin
   • ifosfamide
   • cyclophosphamide
5. ANC and platelet count: Patients must have an ANC >1 × 109/L and a platelet count >100 × 109/L to be eligible for therapy at the start of CTX.
6. Normal cardiac, renal, and hepatic function.
7. All subjects must have a life expectancy of 12 weeks or more.

8. Performance Status: Lansky performance score >60 (age 1 to <16 years).

   • More criteria may apply, please contact the investigator for more information.

Exclusion:

1. Bone marrow involvement.
2. Active myelogenous leukemia or history of myelogenous leukemia.
3. Previous treatment with colony-stimulating factors (granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, interleukin 11 [IL-11]) less than 6 weeks prior to study entry.
4. History of congenital neutropenia or cyclic neutropenia.
5. Pregnant or nursing female patients.
6. Fertile patients who do not agree to use highly reliable contraceptive measures Prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow within the 4 weeks prior to the first tbo-filgrastim dose.
7. Ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit.

8. Treatment with lithium at screening or planned during the study

   • More criteria may apply, please contact the investigator for more information.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: tbo-filgrastim; Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site	Drug: tbo-filgrastim; 5 μg/kg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participants With Adverse Events (AEs)	An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. A treatment-emergent AE (TEAE) is an AE occurring during the timeframe. A non-TEAE is any AE not considered a TEAE. Severity was rated by the investigator using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale where 3=severe but not life-threatening, 4=life-threatening and 5=death. Relation of AE to treatment was determined by the investigator (related=reasonable possibility). Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.	Non-TEAE: signing of informed consent to Day -1 (last day of CTX in week 1). And > 30 days after last dose of tbo-filgrastim (Day 46+). TEAE timeframe: Day 1 (start of tbo-filgrastim) to <= 30 days after the last dose (up to Day 45)
Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results	Serum chemistry tests included alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin, indirect bilirubin, total bilirubin, calcium, creatinine, gammaglutamyl transpeptidase (GGT), glucose, potassium, lactate dehydrogenase (LDH), phosphate, sodium and uric acid. Only tests with potentially clinically significant abnormal results are reported. ULN = upper limit of normal	Day 1 (start of tbo-filgrastim administration) up to Day 21
Participants With Potentially Clinically Significant Abnormal Hematology Results	Hematology tests included Basophils ABS (x 10^9/L), Basophils (%), Eosinophils ABS (x 10^9/L), Eosinophils (%), Hematocrit (%), Hemoglobin (g/L), Lymphocytes Absolute Count (ABS) (x 10^9/L), Lymphocytes (%), Monocytes ABS (x 10^9/L), Monocytes (%), Neutrophils ABS (x 10^9/L), Neutrophils (%), Platelets (x 10^9/L), Red Blood Cell (RBC) (x 10^12/L), White Blood Cell (WBC) (x 10^9/L). Only tests with potentially clinically significant abnormal results are reported. ULN = upper limit of normal	Day 1 (start of tbo-filgrastim administration) up to Day 21
Participants With Potentially Clinically Significant Abnormal Vital Signs	Vital sign tests included Pulse Rate (bpm), Systolic BP (mmHg), Diastolic BP (mmHg), Respiratory Rate (bpm), and Temperature (°C). Only tests with potentially clinically significant abnormal results are reported.	Day 1 (start of tbo-filgrastim administration) up to Day 21
Participants With Potentially Clinically Significant Abnormal Electrocardiogram Results	Triplicate 12-lead ECGs were conducted at screening, predose, 4 and 6 hours postdose on day 1 of tbo-filgrastim administration, and at the end-of-study visit. The ECGs were interpreted by both the investigator and a qualified physician at the central diagnostic center as normal, abnormal not clinically significant, or abnormal clinically significant. The following parameters were measured/derived for each ECG assessment: heart rate, PR interval, RR interval, QT interval, corrected QT interval according to Fridericia's formula (QTcF), corrected QT interval according to Bazett's formula (QTcB), QRS duration, and QRS axis. The count of participants with potentially clinically significant ECG findings is reported.	Day 1 (start of tbo-filgrastim administration) pre-dose, 4 hours post dose and 6 hours post dose; Day 21 (end of study visit)
Participants With Negative Shifts From Baseline to End of Study in Physical Exam Findings	Physical examination was performed at screening and at the end-of-study visit. The following body systems were marked as normal or abnormal and if abnormal, whether clinically significant: Head, ears, eyes, nose and throat (HEENT), chest and lungs, heart, abdomen, skin, lymph nodes and neurological. Any physical examination finding that is judged by the investigator as a clinically significant change (worsening) compared with a baseline value were considered as an adverse event. Counts of participants with a negative shift from baseline in any of the body systems (including shifts from normal to abnormal, not clinically significant) are presented.	Baseline: Day -21, Day 21 (end of study visit)
Participants With Injection Site Reactions to Tbo-Filgrastim Administration	Using Local Tolerability Assessment Scale ranging from Pain severity 0 (Absent) to 3 (Spontaneously painful)	Day 1 (start of tbo-filgrastim administration) up to Day 14
Participants With Negative Shifts From Baseline to End of Study in Spleen Sonography Findings	The investigator assessed spleen sonography findings as normal, abnormal not clinically significant, or abnormal clinically significant. Data representing counts of participants with a negative shift from baseline in spleen sonography findings (including shifts from normal to abnormal, not clinically significant) are presented.	Baseline: Day -21, Day 21 (end of study visit)
Participants Who Were Alive at the 90 Day Follow-Up	Summary of participant survival at 90 day follow-up.	90 days post end of study visit (111 days from start of tbo-filgrastim administration)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participants With Positive Immunogenicity Findings Tested at Four Study Timepoints	Blood was drawn for the assessment of anti-drug antibody (ADA) at screening, at the end-of-study visit, and at 30 and 90 days after the last administration of tbo-filgrastim in chemotherapy (CTX) cycle 1. The main endpoint from the assessment was the presence of antibodies in the sample, reported as positive or negative. Participants with positive results are summarized.	Baseline (Day -21), Day 21 (end of study visit), Day 51 (30 Day follow-up) and Day 111 (90 Day follow-up)
Maximum Observed Serum Concentration (Cmax) of Tbo-Filgrastim		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Time to Maximum Observed Serum Concentration (Tmax) of Tbo-Filgrastim		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Area Under The Serum Concentration-Time Curve From Time 0 To Time Of Last Quantifiable Concentration (AUClast)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Area Under The Serum Concentration-Time Curve From Time 0 To 12 Hours Postdose (AUC0-12)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
AUC From Time 0 to Infinity (AUC0-inf)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Elimination Half-life (t1/2)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Apparent Clearance (CL/F)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose of Day 1
Apparent Volume of Distribution During the Terminal Phase (Vz/F)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Percentage of the AUC0-∞ That Is Due To the Extrapolation (%AUCext)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Terminal Elimination Rate (Lambda-z)		Within 1 hour before the tbo-filgrastim dose and at 2, 4, 6, 8, and 12 hours after the tbo-filgrastim dose on Day 1
Participants With Severe Neutropenia	Count of participants who had an incidence of severe neutropenia, defined as any value of absolute neutrophil count (ANC) <0.5 * 10^9/L at any time.	ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Duration of Severe Neutropenia	The duration of severe neutropenia was derived by counting the number of days with absolute neutrophil count (ANC) values <0.5 * 10^9/L.	ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Area Under The Serum Drug Concentration By Time Curve Of Absolute Neutrophil Count (AUC ANC)		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Absolute Neutrophil Count (ANC) Nadir	ANC nadir (measured in 10^9/L) is the lowest ANC recorded.	ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to Absolute Neutrophil Count (ANC) Nadir From Beginning of Tbo-filgrastim Administration		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to Absolute Neutrophil Count (ANC) Nadir From Beginning of Chemotherapy		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to ANC Recovery To ≥1.0 * 10^9/L From ANC Nadir		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to ANC Recovery To ≥2.0 * 10^9/L From ANC Nadir		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to ANC Recovery To ≥1.0 * 10^9/L From Start of Tbo-filgrastim Administration		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to ANC Recovery To ≥2.0 * 10^9/L From Start of Tbo-filgrastim Administration		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to ANC Recovery To ≥1.0 * 10^9/L From Start of Chemotherapy		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Time to ANC Recovery To ≥2.0 * 10^9/L From Start of Chemotherapy		ANC blood samples collected within 1 hour before the tbo-filgrastim dose on Day 1, and on Days 5, 6, 7, 10, 12, 15 and at the end of study visit (up to Day 21)
Participants With Febrile Neutropenia During the First Cycle of Chemotherapy	Febrile neutropenia was defined as an axillary or external ear temperature >38.3°C (100.94°F) or 2 consecutive readings >37.8°C (100.04°F) at least 2 hours apart and an ANC <0.5 * 10^9/L. The efficacy variable was evaluated for up to 21 days from the start of the first cycle of chemotherapy.	(relative to tbo-filgrastim therapy) Days -7 to Day 14

Collaborators and Investigators

• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): May 12, 2015
• Primary Completion (Actual): April 4, 2017
• Study Completion (Actual): April 4, 2017

Study Registration Dates

• First Submitted: July 11, 2014
• First Submitted That Met QC Criteria: July 11, 2014
• First Posted (Estimate): July 15, 2014

Study Record Updates

• Last Update Posted (Actual): December 10, 2021
• Last Update Submitted That Met QC Criteria: December 8, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: Neutropenia
• Additional Relevant MeSH Terms: Hematologic Diseases; Agranulocytosis; Leukopenia; Leukocyte Disorders; Neutropenia; Physiological Effects of Drugs; Immunologic Factors; Adjuvants, Immunologic; Lenograstim
• Other Study ID Numbers: XM02-ONC-201; 2014-001772-55 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No